This article is more than 5 years old. Information may no longer be current.

FDA approves ablation catheters for treatment of atrial flutter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Boston Scientific announced that the FDA approved two navigation-enabled ablation catheters for treatment of type I atrial flutter.

The magnetically tracked catheters (IntellaNav XP and IntellaNav MiFi XP) are used with a mapping system (Rhythmia, Boston Scientific) and are being launched in conjunction with an enhancement to the mapping system’s software, according to a press release from the company.

Each catheter has a magnetic sensor that tracks its location while it delivers radiofrequency energy during an ablation procedure, and the IntellaNav MiFi XP also has mini-electrode technology to deliver a highly localized signal, according to the release.

The upgrade to the mapping system software enables improved speed, image quality and editing capabilities, the company stated in the release.